DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lgrn5g/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Actelion Ltd
- Alaxia SAS
- AlgiPharma AS
- Arcturus Therapeutics, Inc
- Bayer AG
- Beech Tree Labs, Inc.
- Carolus Therapeutics, Inc.
- Celsus Therapeutics Plc
- Celtaxsys, Inc.
- Chiesi Farmaceutici SpA
- Cilian AG
- Concert Pharmaceuticals, Inc.
- Corbus pharmaceuticals, Inc.
- Cubist Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- Grifols, S.A.
- Invion Limited
- InvivoGen Therapeutics
- JHL Biotech, Inc.
- NanoBio Corporation
- Nostrum Pharmaceuticals, LLC
- Novabiotics Ltd
- Novartis AG
- Pfizer Inc.
- Pharmaxis Limited
- Progenra, Inc.
- ProQR Therapeutics N.V.
- Protalix BioTherapeutics, Inc.
- PTC Therapeutics, Inc.
- Pulmatrix, Inc.
- Shire Plc
- Synovo GmbH
- Verona Pharma Plc
- Vertex Pharmaceuticals Incorporated
- Xenetic Biosciences plc
For more information visit http://www.researchandmarkets.com/research/lgrn5g/cystic_fibrosis
